Amedeo Smart

Free Medical Literature Service


 

Amedeo

Ovarian Neoplasms

  Free Subscription

Articles published in
J Clin Oncol
    September 2021
  1. HAMANISHI J, Takeshima N, Katsumata N, Ushijima K, et al
    Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA).
    J Clin Oncol. 2021 Sep 2:JCO2100334. doi: 10.1200/JCO.21.00334.
    >> Share

    May 2021
  2. ZIVANOVIC O, Chi DS, Zhou Q, Iasonos A, et al
    Secondary Cytoreduction and Carboplatin Hyperthermic Intraperitoneal Chemotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: An MSK Team Ovary Phase II Study.
    J Clin Oncol. 2021 May 21:JCO2100605. doi: 10.1200/JCO.21.00605.
    >> Share

    April 2021
  3. MOORE KN, Bookman M, Sehouli J, Miller A, et al
    Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39).
    J Clin Oncol. 2021 Apr 23:JCO2100306. doi: 10.1200/JCO.21.00306.
    >> Share

  4. KONSTANTINOPOULOS PA, Cannistra SA
    Immune Checkpoint Inhibitors in Ovarian Cancer: Can We Bridge the Gap Between IMagynation and Reality?
    J Clin Oncol. 2021 Apr 23:JCO2100571. doi: 10.1200/JCO.21.00571.
    >> Share

    February 2021
  5. KURIAN AW, Ward KC, Abrahamse P, Bondarenko I, et al
    Time Trends in Receipt of Germline Genetic Testing and Results for Women Diagnosed With Breast Cancer or Ovarian Cancer, 2012-2019.
    J Clin Oncol. 2021 Feb 9:JCO2002785. doi: 10.1200/JCO.20.02785.
    >> Share

    November 2020
  6. MONK BJ, Grisham RN, Banerjee S, Kalbacher E, et al
    MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum.
    J Clin Oncol. 2020;38:3753-3762.
    >> Share

    October 2020
  7. OZA AM, Lorusso D, Aghajanian C, Oaknin A, et al
    Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma.
    J Clin Oncol. 2020;38:3494-3505.
    >> Share

    September 2020
  8. GERSHENSON DM, Gourley C, Paul J
    MEK Inhibitors for the Treatment of Low-Grade Serous Ovarian Cancer: Expanding Therapeutic Options for a Rare Ovarian Cancer Subtype.
    J Clin Oncol. 2020 Sep 8:JCO2002190. doi: 10.1200/JCO.20.02190.
    >> Share

    August 2020
  9. TEW WP, Lacchetti C, Ellis A, Maxian K, et al
    PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline.
    J Clin Oncol. 2020 Aug 13:JCO2001924. doi: 10.1200/JCO.20.01924.
    >> Share

  10. PAULINO E, Melo AC
    SOLO 3 Trial: How Do the Results Fit in With Current Evidence?
    J Clin Oncol. 2020;38:2697-2698.
    >> Share

  11. PENSON RT, Lowe ES
    Reply to E. Paulino et al.
    J Clin Oncol. 2020;38:2698.
    >> Share

  12. DISILVESTRO P, Colombo N, Scambia G, Kim BG, et al
    Efficacy of Maintenance Olaparib for Patients With Newly Diagnosed Advanced Ovarian Cancer With a BRCA Mutation: Subgroup Analysis Findings From the SOLO1 Trial.
    J Clin Oncol. 2020 Aug 4:JCO2000799. doi: 10.1200/JCO.20.00799.
    >> Share

    April 2020
  13. ZAMARIN D, Burger RA, Sill MW, Powell DJ Jr, et al
    Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study.
    J Clin Oncol. 2020 Apr 10:JCO1902059. doi: 10.1200/JCO.19.02059.
    >> Share

    March 2020
  14. BEEBE-DIMMER JL, Kapron AL, Fraser AM, Smith KR, et al
    Risk of Prostate Cancer Associated With Familial and Hereditary Cancer Syndromes.
    J Clin Oncol. 2020 Mar 24:JCO1902808. doi: 10.1200/JCO.19.02808.
    >> Share

  15. YANG X, Leslie G, Doroszuk A, Schneider S, et al
    Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families.
    J Clin Oncol. 2020;38:674-685.
    >> Share

    February 2020
  16. PENSON RT, Valencia RV, Cibula D, Colombo N, et al
    Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial.
    J Clin Oncol. 2020 Feb 19:JCO1902745. doi: 10.1200/JCO.19.02745.
    >> Share

    January 2020
  17. KONSTANTINOPOULOS PA, Norquist B, Lacchetti C, Armstrong D, et al
    Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline.
    J Clin Oncol. 2020 Jan 27:JCO1902960. doi: 10.1200/JCO.19.02960.
    >> Share

  18. TEWARI KS, Monk BJ, Burger RA
    Reply to Farolfi et al and Haines et al.
    J Clin Oncol. 2020;38:173-174.
    >> Share

    November 2019
  19. HAINES IE, Gabor Miklos GL
    Bevacizumab Moonshots: An Important Outcome From the Latest Ovarian Cancer Mission.
    J Clin Oncol. 2019 Nov 7:JCO1901912. doi: 10.1200/JCO.19.01912.
    >> Share

  20. FAROLFI A, Lorusso D, Pignata S, De Giorgi U, et al
    Bevacizumab As Maintenance Treatment in Patients With Ovarian Cancer: Wait for BRCA Testing.
    J Clin Oncol. 2019 Nov 7:JCO1902055. doi: 10.1200/JCO.19.02055.
    >> Share

    September 2019
  21. DE JAEGHERE EA, Gremonprez FB, Tummers PG, Willaert WC, et al
    Treatment of Ovarian Cancer With Intraperitoneal Platinum: Heating Up the Debate.
    J Clin Oncol. 2019 Sep 25:JCO1901179. doi: 10.1200/JCO.19.01179.
    >> Share

  22. TOMAO F, Benedetti Panici P, Tomao S
    Intraperitoneal Chemotherapy in Advanced Ovarian Cancer: Old and Novel Questions.
    J Clin Oncol. 2019 Sep 25:JCO1901163. doi: 10.1200/JCO.19.01163.
    >> Share

  23. MATULONIS UA, Walder L, Nottrup TJ, Bessette P, et al
    Niraparib Maintenance Treatment Improves Time Without Symptoms or Toxicity (TWiST) Versus Routine Surveillance in Recurrent Ovarian Cancer: A TWiST Analysis of the ENGOT-OV16/NOVA Trial.
    J Clin Oncol. 2019 Sep 16:JCO1900917. doi: 10.1200/JCO.19.00917.
    >> Share

    August 2019
  24. BUCKANOVICH RJ, Rustin G, Uppal S, Olawaiye AB, et al
    No Role for Maintenance Bevacizumab for Up-Front Stage IIIc (R0) Ovarian Cancer.
    J Clin Oncol. 2019 Aug 26:JCO1901650. doi: 10.1200/JCO.19.01650.
    >> Share

  25. VERGOTE I, Harter P, Chiva L
    Is There a Role for Intraperitoneal Chemotherapy, Including HIPEC, in the Management of Ovarian Cancer?
    J Clin Oncol. 2019 Aug 12:JCO1900091. doi: 10.1200/JCO.19.00091.
    >> Share

  26. PUJADE-LAURAINE E, Banerjee S, Pignata S
    Management of Platinum-Resistant, Relapsed Epithelial Ovarian Cancer and New Drug Perspectives.
    J Clin Oncol. 2019 Aug 12:JCO1900194. doi: 10.1200/JCO.19.00194.
    >> Share

  27. GERSHENSON DM, Okamoto A, Ray-Coquard I
    Management of Rare Ovarian Cancer Histologies.
    J Clin Oncol. 2019 Aug 12:JCO1802419. doi: 10.1200/JCO.18.02419.
    >> Share

  28. DU BOIS A, Baert T, Vergote I
    Role of Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer.
    J Clin Oncol. 2019 Aug 12:JCO1900022. doi: 10.1200/JCO.19.00022.
    >> Share

  29. ARMSTRONG DK, Walker JL
    Role of Intraperitoneal Therapy in the Initial Management of Ovarian Cancer.
    J Clin Oncol. 2019 Aug 12:JCO1900671. doi: 10.1200/JCO.19.00671.
    >> Share

  30. BOUBERHAN S, Pujade-Lauraine E, Cannistra SA
    Advances in the Management of Platinum-Sensitive Relapsed Ovarian Cancer.
    J Clin Oncol. 2019 Aug 12:JCO1900314. doi: 10.1200/JCO.19.00314.
    >> Share

  31. GOURLEY C, Bookman MA
    Evolving Concepts in the Management of Newly Diagnosed Epithelial Ovarian Cancer.
    J Clin Oncol. 2019 Aug 12:JCO1900337. doi: 10.1200/JCO.19.00337.
    >> Share

  32. KANDALAFT LE, Odunsi K, Coukos G
    Immunotherapy in Ovarian Cancer: Are We There Yet?
    J Clin Oncol. 2019 Aug 12:JCO1900508. doi: 10.1200/JCO.19.00508.
    >> Share

    June 2019
  33. KOOLE SN, van Lieshout C, van Driel WJ, van Schagen E, et al
    Cost Effectiveness of Interval Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy in Stage III Ovarian Cancer on the Basis of a Randomized Phase III Trial.
    J Clin Oncol. 2019 Jun 28:JCO1900594. doi: 10.1200/JCO.19.00594.
    >> Share

  34. TEWARI KS, Burger RA, Enserro D, Norquist BM, et al
    Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer.
    J Clin Oncol. 2019 Jun 19:JCO1901009. doi: 10.1200/JCO.19.01009.
    >> Share

  35. DEL CAMPO JM, Matulonis UA, Malander S, Provencher D, et al
    Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial.
    J Clin Oncol. 2019 Jun 7:JCO1802238. doi: 10.1200/JCO.18.02238.
    >> Share

    April 2019
  36. BOUBERHAN S, Shea M, Cannistra SA
    Advanced Epithelial Ovarian Cancer: Do More Options Mean Greater Benefits?
    J Clin Oncol. 2019 Apr 19:JCO1900500. doi: 10.1200/JCO.19.00500.
    >> Share

  37. BAE JM, Chung KY, Yun SJ, Kim H, et al
    Markedly Reduced Risk of Internal Malignancies in Patients With Vitiligo: A Nationwide Population-Based Cohort Study.
    J Clin Oncol. 2019;37:903-911.
    >> Share

  38. KURIAN AW, Ward KC, Howlader N, Deapen D, et al
    Genetic Testing and Results in a Population-Based Cohort of Breast Cancer Patients and Ovarian Cancer Patients.
    J Clin Oncol. 2019 Apr 9:JCO1801854. doi: 10.1200/JCO.18.01854.
    >> Share

    February 2019
  39. FONSECA A, Xia C, Lorenzo AJ, Krailo M, et al
    Detection of Relapse by Tumor Markers Versus Imaging in Children and Adolescents With Nongerminomatous Malignant Germ Cell Tumors: A Report From the Children's Oncology Group.
    J Clin Oncol. 2019;37:396-402.
    >> Share

    January 2019
  40. BOULAY RM
    The Boy I Never Knew.
    J Clin Oncol. 2019;37:254-255.
    >> Share

    March 2018
  41. COLOMBO N, Huang G, Scambia G, Chalas E, et al
    Evaluation of a Streamlined Oncologist-Led BRCA Mutation Testing and Counseling Model for Patients With Ovarian Cancer.
    J Clin Oncol. 2018 Mar 20:JCO2017762781. doi: 10.1200/JCO.2017.76.2781.
    >> Share

    October 2017
  42. BERCHUCK A, Secord AA, Moss HA, Havrilesky LJ, et al
    Maintenance Poly (ADP-ribose) Polymerase Inhibitor Therapy for Ovarian Cancer: Precision Oncology or One Size Fits All?
    J Clin Oncol. 2017 Oct 26:JCO2017745752. doi: 10.1200/JCO.2017.74.5752.
    >> Share

    August 2017
  43. PIGNATA S, Scambia G, Bologna A, Signoriello S, et al
    Randomized Controlled Trial Testing the Efficacy of Platinum-Free Interval Prolongation in Advanced Ovarian Cancer: The MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG Study.
    J Clin Oncol. 2017 Aug 21:JCO2017734293. doi: 10.1200/JCO.2017.73.4293.
    >> Share

  44. CHILDERS CP, Childers KK, Maggard-Gibbons M, Macinko J, et al
    National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer.
    J Clin Oncol. 2017 Aug 18:JCO2017736314. doi: 10.1200/JCO.2017.73.6314.
    >> Share

    July 2017
  45. SAMIMI G, Bernardini MQ, Brody LC, Caga-Anan CF, et al
    Traceback: A Proposed Framework to Increase Identification and Genetic Counseling of BRCA1 and BRCA2 Mutation Carriers Through Family-Based Outreach.
    J Clin Oncol. 2017;35:2329-2337.
    >> Share

  46. WILLMANN JK, Bonomo L, Carla Testa A, Rinaldi P, et al
    Ultrasound Molecular Imaging With BR55 in Patients With Breast and Ovarian Lesions: First-in-Human Results.
    J Clin Oncol. 2017;35:2133-2140.
    >> Share

    May 2017
  47. BERCHUCK A, Havrilesky LJ, Kauff ND
    Is There a Role for Ovarian Cancer Screening in High-Risk Women?
    J Clin Oncol. 2017;35:1384-1386.
    >> Share

    April 2017
  48. CHRISTIE EL, Fereday S, Doig K, Pattnaik S, et al
    Reversion of BRCA1/2 Germline Mutations Detected in Circulating Tumor DNA From Patients With High-Grade Serous Ovarian Cancer.
    J Clin Oncol. 2017;35:1274-1280.
    >> Share

  49. KONECNY GE
    Understanding Exceptional Responses to Poly (ADP-ribose) Polymerase Inhibition in Sporadic Ovarian Cancer.
    J Clin Oncol. 2017;35:1151-1153.
    >> Share

  50. SHAIKH F, Cullen JW, Olson TA, Pashankar F, et al
    Reduced and Compressed Cisplatin-Based Chemotherapy in Children and Adolescents With Intermediate-Risk Extracranial Malignant Germ Cell Tumors: A Report From the Children's Oncology Group.
    J Clin Oncol. 2017;35:1203-1210.
    >> Share

  51. LHEUREUX S, Bruce JP, Burnier JV, Karakasis K, et al
    Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition.
    J Clin Oncol. 2017;35:1240-1249.
    >> Share

  52. TAYLOR JS, Rajan SS, Zhang N, Meyer LA, et al
    End-of-Life Racial and Ethnic Disparities Among Patients With Ovarian Cancer.
    J Clin Oncol. 2017 Apr 7:JCO2016702894. doi: 10.1200/JCO.2016.70.2894.
    >> Share

  53. GERSHENSON DM, Bodurka DC, Coleman RL, Lu KH, et al
    Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum.
    J Clin Oncol. 2017;35:1103-1111.
    >> Share

  54. MOORE KN, Martin LP, O'Malley DM, Matulonis UA, et al
    Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study.
    J Clin Oncol. 2017;35:1112-1118.
    >> Share

    February 2017
  55. ROSENTHAL AN, Fraser LS, Philpott S, Manchanda R, et al
    Evidence of Stage Shift in Women Diagnosed With Ovarian Cancer During Phase II of the United Kingdom Familial Ovarian Cancer Screening Study.
    J Clin Oncol. 2017 Feb 27:JCO2016699330. doi: 10.1200/JCO.2016.69.9330.
    >> Share

    January 2017
  56. FOTOPOULOU C, Sehouli J, Aletti G, Harter P, et al
    Value of Neoadjuvant Chemotherapy for Newly Diagnosed Advanced Ovarian Cancer: A European Perspective.
    J Clin Oncol. 2017 Jan 9:JCO2016710723.
    >> Share

    December 2016
  57. RUTTEN MJ, van Meurs HS, van de Vrie R, Gaarenstroom KN, et al
    Laparoscopy to Predict the Result of Primary Cytoreductive Surgery in Patients With Advanced Ovarian Cancer: A Randomized Controlled Trial.
    J Clin Oncol. 2016 Dec 28:JCO2016692962.
    >> Share

  58. COPUR MS, Gauchan D, Ramaekers R, Crockett D, et al
    Neoadjuvant Chemotherapy or Primary Debulking Surgery for Stage IIIC Ovarian Cancer.
    J Clin Oncol. 2016 Dec 28:JCO2016707125.
    >> Share

  59. LIU JF, Ray-Coquard I, Selle F, Poveda AM, et al
    Randomized Phase II Trial of Seribantumab in Combination With Paclitaxel in Patients With Advanced Platinum-Resistant or -Refractory Ovarian Cancer.
    J Clin Oncol. 2016;34:4345-4353.
    >> Share

  60. SCHRAM AM, Iasonos A, Hyman DM
    Picking the Right Patient for Human Epidermal Growth Factor Receptor 3-Targeted Therapy in Platinum-Resistant Ovarian Cancer.
    J Clin Oncol. 2016;34:4312-4314.
    >> Share

  61. LEIJEN S, van Geel RM, Sonke GS, de Jong D, et al
    Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months.
    J Clin Oncol. 2016;34:4354-4361.
    >> Share

    March 2016
  62. TUNG N, Lin NU, Kidd J, Allen BA, et al
    Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer.
    J Clin Oncol. 2016 Mar 14. pii: JCO650747.
    >> Share

    January 2016
  63. HORN C, Campbell G, Hagan T, Bovbjerg DH, et al
    Associations between peripheral neuropathy and nausea/vomiting in survivors of ovarian cancer: Evidence of persistent vagal neuropathies?
    J Clin Oncol. 2016;34.
    >> Share

  64. ANGARITA A, Cristello A, Lippitt M, Nickles Fader A, et al
    The "little big things": A qualitative study of ovarian cancer survivors and their experiences with the health care system.
    J Clin Oncol. 2016;34.
    >> Share

  65. GASPARRI ML, Crispino S, La Russa C, Marchetti C, et al
    A 10-year age-related survival analysis on cytoreductive surgery in stage IIIC-IV ovarian cancer: Elderly versus younger women.
    J Clin Oncol. 2016;34.
    >> Share

  66. BLACKMON JE, Recklitis CJ, Wright AA
    Preliminary results from the Sexual Therapy and Rehabilitation after Treatment for Ovarian Cancer (START-OC) study.
    J Clin Oncol. 2016;34.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016